Cellectis (CLLS)

• Market cap: $355M
• 1 day: -3.8%
• 5 days: -31.92%
• 1 month: -3.54%
• 3 months: 91.35%
• 6 months: 145.83%
• Year to date: 95.58%
• 1 year: 96.67%
• 5 years: -80.17%
• 10 years: -86.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222